CANCER:

Lung Adenocarcinoma

Related cancers:

‹

Non Small Cell Lung Cancer (2052)

Lung Non-Small Cell Squamous Cancer (66)

Lung Non-Squamous Non-Small Cell Cancer (65)

Non Small Cell Lung Cancer (2052)

Lung Non-Small Cell Squamous Cancer (66)

Lung Non-Squamous Non-Small Cell Cancer (65)

›

BRAF V600 BRAF V600	Lung Adenocarcinoma LUAD	trametinib + dabrafenib + osimertinib Sensitive: C4 – Case Studies Lung Cancer - 1 week
No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	erlotinib Resistant: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	atezolizumab Sensitive: C1 - Off-label
MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	tepotinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label
BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	olaparib Sensitive: C1 - Off-label
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C1 - Off-label
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C1 - Off-label
RET fusion RET fusion	Lung Adenocarcinoma LUAD	pralsetinib Sensitive: C1 - Off-label
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	cetuximab + afatinib Sensitive: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + afatinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR-RAD51 fusion EGFR-RAD51 fusion	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
SNX20 overexpression + PD-L1 overexpression SNX20 overexpression + PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Sensitive: C3 – Early Trials
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials
EGFR mutation + MDM4 32C>A EGFR mutation + MDM4 32C>A	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
KEAP1 mutation + MSI-L/dMMR KEAP1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
IFI27 underexpression IFI27 underexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR overexpression EGFR overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials
ALK positive ALK positive	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR exon 21 mutation EGFR exon 21 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials
EGFR mutation + PIK3CA mutation EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR mutation + TP53 mutation EGFR mutation + TP53 mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials
CD74-NRG1 fusion CD74-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
YBX1 overexpression YBX1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
SMARCA4 mutation SMARCA4 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation PBRM1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + MSI-L/dMMR PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + TMB-L + MSI-L/dMMR BRAF mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + TMB-L + MSI-L/dMMR PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	erlotinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials
SDC4-NRG1 fusion SDC4-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
POLD1 C284Y POLD1 C284Y	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials
MET D1010N MET D1010N	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials
SCN8A Q225X SCN8A Q225X	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials
MET amplification MET amplification	Lung Adenocarcinoma LUAD	crizotinib + osimertinib Sensitive: C3 – Early Trials
HER-2 underexpression HER-2 underexpression	Lung Adenocarcinoma LUAD	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
EGFR G719A + S768I EGFR G719A + S768I	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
EGFR G719C + S768I EGFR G719C + S768I	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
EGFR L858R + R776H EGFR L858R + R776H	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials
EGFR D761Y EGFR D761Y	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials

Lung Adenocarcinoma

Associations(350)

Associations
(350)